Testosterone treatment to mimic hormone physiology in androgen replacement therapy: A view on testosterone gel and other preparations available

Expert Opinion on Biological Therapy

Volumn 7, Issue 7, 2007, Pages 1093-1106

  Fabbri, Andrea ^a   Isidori, Andrea M ^b   Giannetta, Elisa ^b   Lenzi, Andrea ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Ageing; Androgen replacement therapy; Erectile dysfunction; Hypogonadism; Testosterone

Indexed keywords

ANDROGEN; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TESTOCUR; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; DRUG DELIVERY SYSTEMS; GELS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; IMPOTENCE; MALE; PIPERAZINES; PURINES; SULFONES; TESTOSTERONE;

EID: 34547643044     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.7.1093     Document Type: Article

References (101)

1. ARAUJO AB, O'DONNELL AB, BRAMBILLA DJ et al.: Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male ageing study. J. Clin. Endocrinol. Metab. (2004) 89(12):5920-5926.
2. ISIDORI AM, GIANNETTA E, GRECO EA et al.: Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin. Endocrinol. (Oxf). (2005) 63(3):280-293. • One of the most rigorous meta-analysis on non-reproductive effects of androgens.
3. ISIDORI AM, GIANNETTA E, POZZA C, BONIFACIO V, ISIDORI A: Androgens, cardiovascular disease and osteoporosis. J. Endocrinol. Invest. (2005) 28(10 Suppl.):73-79.
4. GOOREN L: Androgen deficiency in the ageing male: benefits and risks of androgen supplementation. J Steroid Biochem. Mol. Biol. (2003) 85(2-5):349-355.
5. ISIDORI AM, GIANNETTA E, GIANFRILLI D et al.: Effects of testosterone on sexual function in men: results of a meta-analysis. Clin. Endocrinol. (Oxf). (2005) 63(4):381-394. • One of the most rigorous meta-analysis on the effect of androgen on sexual function.
6. KORENMAN SG, MORLEY JE, MOORADIAN AD et al.: Secondary hypogonadism in older men: its relation to impotence. J. Clin. Endocrinol. Metab. (1990) 71(4):963-969.
7. KAUFMAN JM, VERMAULEN A: The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. (2005) 26(6):833-876.
8. ISIDORI AM, LENZI A: Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J. Endocrinol. Invest. (2005) 28(3 Suppl.):14-22.
9. ZIRKIN BR, CHEN H: Regulation of Leydig cell steroidogenic function during ageing. Biol. Reprod. (2000) 63(4):977-981. •• Very convincing argumentation of the mechanisms involved in age-related hypogonadism.
10. ISIDORI AM, CAPRIO M, STROLLO F et al.: Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J. Clin. Endocrinol. Metab. (1999) 84(10):3673-3680. •• One of the first experimental demonstration of the impact of obesity on androgen production.
11. ISIDORI AM, STROLLO F, MORE M et al.: Leptin and ageing: correlation with endocrine changes in male and female healthy adult populations of different body weights. J. Clin. Endocrinol. Metab. (2000) 85(5):1954-1962.
12. ALGARTE-GENIN M, CUSSENOT O, COSTA P: Prevention of prostate cancer by androgens: experimental paradox or clinical reality. Eur. Urol. (2004) 46(3):285-294.
13. NIESCHLAG E, BEHRE HM, BOUCHARD P et al.: Testosterone replacement therapy: current trends and future directions. Hum. Reprod. Update (2004) 10(5):409-419. • Very helpful review on androgen replacement therapy.
14. KELLER ET, ERSHLER WB, CHANG C: The androgen receptor: a mediator of diverse responses. Front. Biosci. (1996) 1:D59-D71.
15. GUO Z, BENTEN WP, KRUCKEN J et al.: Nongenomic testosterone calcium signaling. Genotropic actions in androgen receptor-free macrophages. J. Biol. Chem. (2002) 277(33):29600-29607.
16. HIJAZI RA, CUNNINGHAM GR: Andropause: is androgen replacement therapy indicated for the ageing male? Ann. Rev. Med. (2005):56117-56137.
17. HARMAN SM, METTER EJ, TOBIN JD, PEARSON J, BLACKMAN MR: Longitudinal effects of ageing on serum total and free testosterone levels in healthy men. J. Clin. Endocrinol. Metab. (2001) 86(2):724-731.
18. BARTSCH G, RITTMASTER G, KLOCKER H: Dihydrotestosterone and the concept of 5α-reductase inhibition in human prostatic benign hyperplasia. World J. Urol. (2002) 19(6):413-425.
19. LY LP, JIMENEZ M, ZHUANG TN et al.: A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J. Clin. Endocrinol. Metab, (2001) 86(9):4078-4088.
20. HANDELSMAN DJ, CONWAY AJ, BOYLAN LM: Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J. Clin. Endocrinol. Metab. (1990) 71(1):216-222.
21. HANDELSMAN DJ, MACKEY MA, HOWE C, TURNER L, CONWAY AJ: An analysis of testosterone implants for androgen replacement therapy. Clin. Endocrinol. (Oxf). (1997) 47(3):311-316.
22. BEHRE HM, ABSHAGEN K, OETTEL M, HUBLER D, NIESCHLAG E: Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: Phase I studies. Eur. J. Endocrinol. (1999) 140(5):414-419.
23. BEHRE HM, NIESCHLAG E: Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J. Clin. Endocrinol. Metab. (1992) 75(5):1204-1210.
24. SNYDER PJ, LAWRENCE DA: Treatment of male hypogonadism with testosterone enantate. J. Clin. Endocrinol. Metab. (1980) 51(6):1335-1339.
25. DOBS AS, MEIKLE AW, ARVER S et al.: Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enantate for the treatment of hypogonadal men. J. Clin. Endocrinol. Metab. (1999) 84(10):3469-3478.
26. VON ECKARDSTEIN S, NIESCHLAG E: Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a Phase II study. J. Androl. (2002) 23(3):419-425.
27. NADELL J, KOSEK J: Peliosis hepatis. Twelve cases associated with oral androgen therapy. Arch. Pathol. Lab. Med. (1977) 101(8):405-410.
28. OVERLY WL, DANKOFF JA, WANG BK, SINGH UD: Androgens and hepatocellular carcinoma in an athlete. Ann. Intern. Med. (1984) 100(1):158-159.
29. WESTABY D, OGLE SJ, PARADINAS FJ, RANDELL JB, MURRAY-LYON IM: Liver damage from long-term methyltestosterone. Lancet (1977) 2(8032):262-263.
30. GOOREN LJ: A ten-year safety study of the oral androgen testosterone undecanoate. J. Androl. (1994) 15(3):212-215. • One of the very few long-term studies.
31. BOYANOV MA, BONEVA Z, CHRISTOV VG: Testosterone supplementation in men with Type 2 diabetes, visceral obesity and partial androgen deficiency. Ageing Male (2003) 6(1):1-7.
32. MARIN P, HOLMANG S, JONSSON L et al.: The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int. J. Obes. Relat. Metab. Disord. (1992) 16(12):991-997.
33. PARK NC, YAN BQ, CHUNG JM, LEE KM: Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency. Aging Male (2003) 6(2):86-93.
34. UYANIK BS, ARI Z, GUMUS B et al.: Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo-controlled study. Jpn. Heart J. (1997) 38(1):73-82.
35. WITTERT GA, CHAOMAN IM, HAREN MT et al.: Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J. Gerontol. A Biol. Sci. Med. Sci. (2003) 58(7):618-625.
36. BEHRE HM, VON ECKARDSTEIN S, KLIESCH S, NIESCHLAG E: Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years. Clin. Endocrinol (Oxf). (1999) 50(5):629-635. • One of the very few long-term studies (retrospective).
37. CUNNINGHAM GR, CORDERO E, THORNBY JI: Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA (1989) 261(17):2525-2530.
38. DANIELL HW, LENTZ R, MAZER NA: Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain (2006) 7(3):200-210.
39. SNYDER PJ, PAECHEY H, HANNOUSH P et al.: Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab. (1999) 84(8):2647-2653.
40. SNYDER PJ, PAECHEY H, HANNOUSH P et al.: Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. (1999) 84(6):1966-1972.
41. SNYDER PJ, PAECHEY H, BERLIN JA et al.: Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am. J. Med. (2001) 111(4):255-260.
42. MEIKLE AW, ARVER S, DOBS AS et al.: Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site - a clinical research center study. J. Clin. Endocrinol. Metab. (1996) 81(5):1832-1840.
43. WANG C, SWERDLOFF R, KIPNES M et al.: New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J. Clin. Endocrinol Metab. (2004) 89(8):3821-3829.
44. KORBONITS M, SLAWIK M, CULLEN D et al.: A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J. Clin. Endocrinol. Metab. (2004) 89(5):2039-2043.
45. ROSS RJ, JABBAR A, JONES TH et al.: Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. Eur. J. Endocrinol. (2004) 150(1):57-63.
46. DOBS AS, MATSUMOTO AM, WANG C, KIPNES MS: Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr. Med. Res. Opin. (2004) 20(5):729-738.
47. GOOREN LJ, BUNCK MC: Transdermal testosterone delivery: testosterone patch and gel. World J. Urol. (2003) 21(5):316-319.
48. JOCKENHOVEL F: Testosterone supplementation: what and how to give. Ageing Male (2003) 6(3):200-206.
49. BASARIA S, DOBS AS: New modalities of transdermal testosterone replacement. Treat. Endocrinol. (2003) 2(1):1-9.
50. WANG C, SWEDLOFF RS, IRANMANESH A et al.: Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J. Clin. Endocrinol. Metab. (2000) 85(8):2839-2853.
51. KUHNERT B, BYRNE M, SIMONI M et al.: Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur. J. Endocrinol. (2005) 153(2):317-326.
52. MAZER N, BELL D, WU J et al.: Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. J. Sex Med. (2005) 2(2):213-226.
53. SWERDLOFF RS, WANG C, CUNNINGHAM G et al.: Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J. Clin. Endocrinol. Metab. (2000) 85(12):4500-4510.
54. WANG C, BERMAN N, LONGSTRETH JA et al.: Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J. Clin. Endocrinol. Metab. (2000) 85(3):964-969.
55. WANG C, IRANMANESH A, BERMAN N et al.: Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men - a clinical research center study. J. Clin. Endocrinol. Metab. (1998) 83(8):2749-2757.
56. MAZER N, FISHER D, FISCHER J et al.: Transfer of transdermally applied testosterone to clothing: a comparison of a testosterone patch versus a testosterone gel. J. Sex Med. (2005) 2(2):227-234.
57. DEAN JD, CARNEGIE C, RODZVILLA J, SMITH T: Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Rev. Urol. (2004) 6(Suppl. 6):S22-S29.
58. STEIDLE C, SCHWATRZ S, JACOBY K, SEBREE T, SMITH T, BACHAND R; NORTH AMERICAN AA2500 T GEL STUDY GROUP: AA2500 testosterone gel normalizes androgen levels in ageing males with improvements in body composition and sexual function. J. Clin. Endocrinol. Metab. (2003) 88(6):2673-2681.
59. WANG C, SWEDLOFF RS, IRANMANESH A et al.: Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J. Clin. Endocrinol. Metab. (2000) 85(8):2839-2853.
60. WANG C, CUNNINGHAM G, DOBS A et al.: Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. (2004) 89(5):2085-2098. •• One of the best trial on long-term testosterone replacement.
61. POPE HG Jr, COHANE GH, KANAYAMA G, SIEGEL AJ, HUDSON JI: Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am. J. Psychiatry (2003) 160(1):105-111.
62. ORENGO CA, FULLERTON L, KUNIK ME: Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J. Geriatr. Psychiatry Neurol. (2005) 18(1):20-24.
63. CARNAHAN RM, PERRY PJ: Depression in ageing men: the role of testosterone. Drugs Ageing (2004) 21(6):361-376.
64. MARGO K, WINN R: Testosterone treatments: why, when, and how? Am. Earn. Physician (2006) 73(9):1591-1598 (Review).
65. Summary for patients in: Am. Earn. Physician (2006) 73(9):1603.
66. ROLF C, KNIE U, LEMMNITZ G, NIESCHLAG E: Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin. Endocrinol. (Oxf). (2002) 56(5):637-641.
67. BUVAT J, LEMAIRE A: Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J. Urol. (1997) 158(5):1764-1767.
68. JAIN P, RADEMAKER AW, MCVARY KT: Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J. Urol. (2000) 164(2):371-375.
69. AVERSA A, ISIDORI AM, DE MARTINO MU et al.: Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin. Endocrinol. (Oxf). (2000) 53(4):517-522. • One the earlier clinical studies documenting the effect of testosterone on erection.
70. AVERSA A, ISIDORI AM, SPERA G, LENZI A, FABBRI A: Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin. Endocrinol. (Oxf). (2003) 58(5):632-638. •• The first clinical study on the combined treatment of testosterone and PDE5i.
71. MORELLI A, FILIPPI S, MANCINA R et al.: Androgens regulate phosphodiesterase Type 5 expression and functional activity in corpora cavernosa. Endocrinology (2004) 145(5):2253-2263. •• Fundamental work providing a molecular demonstration of the regulation of PDE5i by androgens.
72. SHABSIGH R: The effects of testosterone on the cavernous tissue and erectile function. World J. Urol. (1997) 15(1):21-26.
73. REILLY CM, ZAMORANO P, STOPPER VS, MILLS TM: Androgenic regulation of NO availability in rat penile erection. J. Androl. (1997) 18(2):110-115.
74. ANDERSSON KE, HOLMQUIST F: Regulation of tone in penile cavernous smooth muscle. Established concepts and new findings. World J. Urol. (1994) 12(5):249-261.
75. BURNETT AL: The role of nitric oxide in erectile dysfunction: implications for medical therapy. J. Clin. Hypertens. (Greenwich) (2006) 8(12 Suppl. 4):53-62.
76. WEBB CM, MCNEILL JG, HAYWARD CS, DE ZEIGLER D, COLLINS P: Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation (1999) 100(16):1690-1696. • Very interesting work on potential vasomotor effect of androgens.
77. CHOU TM, SUDHIR K, HUTCHISON SJ et al.: Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation (1996) 94(10):2614-2619. • Very interesting work on potential vasomotor effect of androgens.
78. HEINLEIN CA, CHANG C: The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol. Endocrinol. (2002) 16(10):2181-2187. •• Important work on additional mechanisms of action of androgens.
79. HWANG TI, CHEN HE, TSAI TF, LIN YC: Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int. J. Impot. Res. (2006) 18(4):400-404.
80. KALINCHENKO SY, KOZLOV GI, GONTCHAROV NP, KATSIYA GV: Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Ageing Male (2003) 6(2):94-99.
81. ROSENTHAL BD, MAY NR, METRO MJ, HARKAWAY RC, GINSBERG PC: Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology (2006) 67(3):571-574.
82. SHAMLOUL R, GHANEM H, FAHMY I et al.: Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J. Sex Med. (2005) 2(4):559-564.
83. ISIDORI AM, GRECO EA, AVERSA A: Androgen deficiency and hormone-replacement therapy. BJU Int. (2005) 96(2):212-216.
84. ARVER S, DOBS AS, MEIKLE AW et al.: Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J. Urol. (1996) 155(5):1604-1608.
85. SHABSIGH R, KAUFMAN JM, STEIDLE C, PADMA-NATHAN H: Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J. Urol. (2004) 172(2):658-663. •• Important work on combined treatment of sildenafil and testosterone.
86. NIESCHLAG E, SWERDLOFF R, BEHRE HM et al.: Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int. J. Androl. (2005) 28(3):125-127. •• Very useful publication with clinical practice guidelines for hypogonadism.
87. MARBURY T, HAMILL E, BACHAND R, SEBREE T, SMITH T: Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim trade mark, compared to AndroGel(R). Biopharm. Drug Dispos. (2003) 24(3):115-120.
88. MCNICHOLAS TA, DEAN JD, MULDER H, CARNEGIE C, JONES NA: A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. (2003) 91(1):69-74.
89. STEIDLE C, SCHWARTZ S, JACOBY K et al.: AA2500 testosterone gel normalizes androgen levels in ageing males with improvements in body composition and sexual function. J. Clin. Endocrinol. Metab. (2003) 88(6):2673-2681. •• High-quality large, controlled clinical trial on testosterone replacement therapy.
90. MCGRIFF-LEE NJ: Transdermal testosterone gel (Cellegy). Curr. Opin. Investig. Drugs (2002) 3(1):1629-1632.
91. JORDAN WP Jr: Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am. J. Contact Dermat. (1997) 8(2):108-113.
92. ROLF C, GOTTSCHALK I, BEHRE HM et al.: Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men. Exp. Clin. Endocrinol. Diabetes (1999) 107(1):63-69.
93. MILLER KK, ROSNER W, LEE H et al.: Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J. Clin. Endocrinol. Metab. (2004) 89(2):525-533.
94. WU FC: Commentary: guideline for male testosterone therapy: a European perspective. J. Clin. Endocrinol. Metab. (2007) 92(2):418-419.
95. MORGENTALER A: Commentary: guideline for male testosterone therapy: a clinician's perspective. J. Clin. Endocrinol. Metab. (2007) 92(2):416-417.
96. SHAMES D, GASSMAN A, HANDELSMAN H: Commentary: guideline for male testosterone therapy: a regulatory. J. Clin. Endocrinol. Metab. (2007) 92(2):414-415.
97. YASSIN AA, SAAD F: Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). World J. Urol. (2006) 24(6):639-644.
98. HARLE L, BASARIA S, DOBS AS: Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin. Pharmacother. (2005) 6(10):1751-1759.
99. CHATTERJEE R, KOTTARIDIS PD, MCGARRIGLE HH, LINCH DC: Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for haematological malignancies. Bone Marrow Transplant. (2002) 29(7):607-610.
100. GREENSTEIN A, MABJEESH NJ, SOFER M et al.: Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J. Urol. (2005) 173(2):530-532.
101. ROCHIRA V, BALESTRIERI A, MADEO B, GRANATA AR, CARANI C: Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J. Androl. (2006) 27(2):165-175.